Compare Linde PLC (LIN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Neurocrine Biosciences Inc — how do they compare? Linde PLC trades at $483.73 (market cap $222.05B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Linde PLC is far larger — about 15.5× Neurocrine Biosciences Inc's market cap, and Linde PLC pays a 1.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LIN | NBIX | |
|---|---|---|
Market Cap | $222.05B | $14.36B |
Volume | 2,116,440 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $185.50 |
52-Week Low | $389.38 | $123.10 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $245.17B | $14.37B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $481.70, down 0.47% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $4.50 beating estimates of $4.49, and maintains healthy profitability with a 20.43% net income margin. Analyst sentiment remains overwhelmingly positive with 89.66% buy ratings and a $557.10 consensus price target representing 15.6% upside potential from current levels.
The outlook remains favorable given Linde's leadership in industrial gases and exposure to AI chip manufacturing growth, though valuation at 31.08 P/E requires continued execution. Key risks include margin pressure from higher capital expenditures and competitive dynamics in the electronics sector. The stock's technical setup suggests support near $479 with resistance at $485, providing clear levels for near-term price action.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
